Anonymous. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329
(14):977–986.
5.
Anonymous. Intensive blood-glucose control with sulphonylureas or insuli compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352
(9131):837–853.
6.
GinsbergHN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. DiabetesCare. 2011;34
(suppl 2):S107–S108.
7.
DuckworthWCMcCarrenMAbrairaC. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocr Pract2006;12
(suppl 1):85–88.
8.
HellerSR; ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care. 2009;32
(suppl 2):S357–S361.
9.
GreggEWLiYWangJ. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370
(16):1514–1523.
10.
HermanWHKennedyL. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care. 2005;28
(6):1480–1481.
11.
PapanasNZieglerD. New vistas in the diagnosis of diabetic polyneuropathy [published online May 17, 2014]. Endocrine.
12.
Anonymous. Diabetes care and research in Europe: the Saint Vincent declaration. Diabet Med. 1990;7
(4):360.
13.
PapanasNMaltezosEEdmondsM. St. Vincent declaration after 15 years or who cleft the devil’s foot?Vasa. 2006;35
(1):3–4.
14.
RathmannWGianiG. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27
(10):2568–2569.
15.
VlassaraHStrikerGE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7
(9):526–539.
16.
PapanasNDemetriouMKatsikiN. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res. 2011;2011:346051.
17.
KatsikiNPapanasNFonsecaVAMaltezosEMikhailidisDP. Uric acid and diabetes: is there a link?Curr Pharm Des. 2013;19
(27):4930–4937.
18.
KatsikiNKaragiannisAMikhailidisDP. Diabetes, bilirubin and amputations: is there a link?Diabetologia. 2013;56
(4):683–685.
19.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother. 2012;13
(2):287–288.
20.
AthyrosVGMikhailidisDP. Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate. Nat Rev Endocrinol. 2012;8
(3):133–134.
21.
AthyrosVGKatsikiNKaragiannisAMikhailidisDP. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease [published online June 20, 2014]. Curr Pharm Des. 2014.
22.
PafiliKPapanasN. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother. 2014;15
(9):1197–1201.
23.
PloskerGL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72
(17):2289–2312.
24.
MoranABundyBBeckerDJ. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381
(9881):1905–1915.
25.
Cavelti-WederCBabians-BrunnerAKellerC. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35
(8):1654–1662.
26.
PafiliKPapanasN. The importance of patient compliance with insulin pens: how can a new user-friendly pen help?Expert Opin Drug Deliv. 2014;11
(5):629–632.
27.
AmosAFMcCartyDJZimmetP. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14
(suppl 5):S1–S85.
28.
IoannidisJP. Why most published research findings are false. PLoS Med. 2005;2
(8):e124.
29.
MatthewsDRTsapasA. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res. 2008;5(3):216–218.
